Life Sciences

  • December 22, 2025

    Apple Seeks To Overturn $634M Masimo Patent Verdict

    Apple has urged a California federal judge to grant its combined motion for judgment or a new trial for its $634 million trial loss over a Masimo patient monitor patent, arguing that no reasonable jury could have reached the verdict and that the tech giant was "severely prejudiced" by erroneous court rulings.

  • December 22, 2025

    6th Circ. Vacates Pharma Salesman's $6.8M Restitution Order

    The Sixth Circuit vacated a nearly $7 million restitution order against a pharmaceutical salesman convicted of healthcare fraud, finding an Ohio federal court erred in calculating that amount and apportioning liability.

  • December 22, 2025

    Fed. Circ. Urged To Preserve Novartis' Bench Trial Loss

    MSN Pharmaceuticals has pushed back against Novartis' efforts to save its case accusing the generic-drug maker of infringing a patent covering the blockbuster cardiovascular drug Entresto, telling the Federal Circuit that the appeal "reveals no district court error, just Novartis' poor litigation strategy."

  • December 19, 2025

    Colo. IVF Co. Says AI Fertility Co. Owes Nearly $900K

    The maker of an in vitro fertilization incubator system has filed a breach of contract lawsuit in Colorado federal court, claiming an artificial intelligence-based fertility company owes it nearly $900,000 for embryoscope incubator systems it sold to the lab.

  • December 19, 2025

    AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims

    A Massachusetts federal judge spared AstraZeneca unit Alexion on Friday from half of a nonprofit insurer's proposed class action, finding the plaintiff too far removed from anticompetitive patent fraud that allegedly propped up blood disorder treatment Soliris, while preserving accusations that Alexion brought sham infringement allegations against would-be rivals.

  • December 19, 2025

    The Top Patent Damages Of 2025

    The largest patent verdict of the year was Apple's $634 million loss against Masimo, and juries issued eight other nine-figure verdicts in 2025 — many of which were against Samsung.

  • December 19, 2025

    Medical, School Groups Seek Order Halting $100K Visa Fee

    A medical practice in rural North Carolina and other employers asked a federal judge Friday to block enforcement of the Trump administration's $100,000 fee on H-1B visas, arguing the "massive" fee hike will inflict irreparable harm on their communities.

  • December 19, 2025

    BigLaw And Boutiques Both Shine In 2025's Top 10 Deals

    A tight circle of elite law firms guided the way as megadeals roared back with force in 2025, while a small group of specialist and international firms also made their mark across global transactions spanning infrastructure, gaming, pharmaceuticals, artificial intelligence and energy.

  • December 19, 2025

    Taxation With Representation: Baker Botts, Morgan Lewis

    In this week's Taxation With Representation, Trump Media and Technology Group merges with fusion power company TAE Technologies, pharmaceutical company Cencora boosts its stake in cancer care company OneOncology, and Phoenix Financial partners with private equity giant Blackstone to plug billions into various credit strategies.

  • December 19, 2025

    J&J, ChemImage Reach Deal After $77M AI Patent Judgment

    Johnson & Johnson has entered an agreement to resolve a lawsuit that ChemImage Corp. had brought alleging the pharmaceutical giant unilaterally ended a deal to develop in-surgery artificial intelligence imaging techniques, after a New York federal judge determined J&J owed $76.6 million in the dispute.

  • December 19, 2025

    AbCellera Gets $36M In Cell Research Patent Settlement

    Canadian biotechnology firm AbCellera said it had reached a $36 million settlement with Bruker Corp. to resolve patent infringement claims related to a cell analysis system.

  • December 19, 2025

    Trump Admin Appeals Harvard Win In $2B Fund Freeze Case

    The Trump administration will ask the First Circuit to overturn a federal judge's ruling that prevented the government from withholding $2.2 billion in federal grants from Harvard University over concerns about antisemitism on campus.

  • December 19, 2025

    Biomedical Co. Gets Approval For Ch. 11 Auction In January

    Eye disease treatment developer Clearside Biomedical on Friday got permission from a Delaware bankruptcy judge for a January auction of its assets after saying it had resolved objections from shareholders and the U.S. Trustee's Office.

  • December 19, 2025

    BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved

    BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics for $4.8 billion, in a deal bolstered by Amicus' settlement of patent litigation that secures U.S. exclusivity for its Galafold drug until 2037, the companies said Friday.

  • December 18, 2025

    The Biggest Rulings From A Busy Year At The 1st Circ.

    The nation's smallest federal appellate panel punched above its weight in 2025, grappling with numerous suits against the Trump administration, high-profile criminal appeals, a $34 million legal fee bid and a hotly contested kickback law.

  • December 18, 2025

    ITC Clears Toy Gun Imports, Will Review Smart Rings, Vapes

    The U.S. International Trade Commission has had a busy week in intellectual property, determining a series of toy gun imports don't infringe Spin Master patents licensed to Hasbro, instituting reviews requested by companies including Ouraring, AbbVie and Juul, and receiving several new complaints.

  • December 18, 2025

    Eli Lilly Workers Say Justices Needn't Mull Collective Standard

    Eli Lilly workers on Wednesday pressed the U.S. Supreme Court not to disturb a Seventh Circuit decision establishing a new, more flexible standard for certifying collective actions, arguing that there's no "urgent" need for the high court to weigh in on the dispute.

  • December 18, 2025

    InnovAge Investors Get Final OK For $27M Deal, Atty Fees

    A Colorado federal judge has granted final approval to a $27 million settlement between InnovAge Holding Corp., its underwriters and a class of stockholders accusing the senior healthcare company of making misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the alleged falsehoods.

  • December 18, 2025

    Top Trade Secrets Decisions Of 2025

    The Ninth Circuit clarified the rules of engagement in trade secrets disputes with guidance on when confidential information must be precisely detailed during litigation, and jurors delivered a $200 million verdict against Walmart over product freshness technology. Here are Law360's picks for the biggest trade secrets decisions of 2025.

  • December 18, 2025

    Top Product Liability Cases Of 2025

    The Fourth Circuit's decision to unravel an early landmark ruling in litigation over the opioid crisis in a suit brought by West Virginia counties against drug distributors tops Law360's list of product liability cases of the past year, as well as a loss for Tesla in a newsworthy trial over the automaker's Autopilot feature. Here's what other cases garnered attorneys' attention in 2025.

  • December 18, 2025

    UC Researchers Near Reinstating $7B In DOE Grants

    A California federal judge said Thursday she's inclined to grant a preliminary injunction ordering the Trump administration to reinstate $7 billion in Department of Energy grants awarded to researchers, saying they were canceled with form letters similar to those she's previously found to violate the Administrative Procedure Act.

  • December 18, 2025

    SF Must Reinstate Worker Fired For Violating COVID Vax Rule

    A California federal judge ordered San Francisco to reinstate a 311 call center agent who was fired for violating a COVID-19 vaccination mandate after he sought an exemption based on his Muslim faith, ruling Thursday that the plaintiff has made a "prima facie case for religious discrimination."

  • December 18, 2025

    AstraZeneca Can't Block Colo. Law Over Drug Discount Rules

    A Colorado federal judge rejected AstraZeneca's effort to block enforcement of a Colorado law surrounding federal 340B drug pricing that requires manufacturers to sell drugs at discounted prices to certain safety net healthcare facilities, ruling Wednesday the law isn't preempted by 340B drug pricing. 

  • December 18, 2025

    HHS Proposes Hospital Ban On Gender Care For Minors

    The Trump administration moved to block all hospitals that receive federal funding from providing gender-affirming care to minors and issued warning letters to a dozen companies Thursday as part of a sweeping push to halt the care nationwide, even in states with legal protections in place.

  • December 18, 2025

    Agita Over Piglets At Party Got Pharma Exec Axed, Suit Says

    The U.S. arm of a Danish pharmaceutical company pushed out a director after he expressed concerns about using baby pigs for a photo op at the company's anniversary party knowing the animals would be euthanized after, a new federal lawsuit alleges.

Expert Analysis

  • Opinion

    Punitive Damages Awards Should Be Limited To 1st Instance

    Author Photo

    Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.

  • How Calif. High Court Is Rethinking Forum Selection Clauses

    Author Photo

    Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Lessons From Fed. Circ. On Expert Testimony In Patent Cases

    Author Photo

    Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.

  • When Atty Ethics Violations Give Rise To Causes Of Action

    Author Photo

    Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

  • Trending At The PTAB: A Potential Barrier To Serial Challenges

    Author Photo

    New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.

  • What's Changing For Cos. In New Calif. Hazardous Waste Plan

    Author Photo

    While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.

  • Fed. Circ. In September: The Printed Matter Doctrine Expands

    Author Photo

    The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.

  • Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split

    Author Photo

    In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.

  • Series

    Practicing Stoicism Makes Me A Better Lawyer

    Author Photo

    Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.

  • Broader Eligibility For AI-Related Patents May Be Coming

    Author Photo

    A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.

  • Series

    The Biz Court Digest: Texas, One Year In

    Author Photo

    A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.

  • AI Product Safety Insights May Expand Foreseeability

    Author Photo

    Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.